BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international Phase 3 trials and global commercialization.Read More
William Blair initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “market perform” rating, citing a possibly tough road ahead for approval of the company’s ataluren in the U.S. The stock closed at $17.72 on Aug. 22.Read More
Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.
3D is a personalized medicine company, with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease.Read More
StemCells (NASDAQ:STEM) and closely-held Microbot Medical of Israel have entered into a definitive merger agreement, with plans to pursue the development of robotics-based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions.
“This transaction concludes an extensive search for strategic alternatives conducted by StemCells since we failed to see robust clinical results in our Phase 2 clinical study of human neural stem cells in chronic spinal cord injury,” Ian Massey, CEO of StemCells, said in a statement.Read More
BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.
The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.Read More
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid arthritis. The company previously had a pre-submission meeting with the EMA.
The global trial is expected to begin in either the second or third quarter of 2016. It will investigate the efficacy and safety of CF101 administered orally twice daily for 16 weeks to patients with active rheumatoid arthritis treated with conventional disease modifying drugs.Read More
Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board.
“The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong track records of success, is consistent with our effort to bring the best talent to NovellusDx and rapidly become the leader in personalized medicine,” CEO, Haim Gil-Ad, said in a statement.Read More
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016.
“We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their efficacy across six major indications,” CEO, Dr. Pnina Fishman, said in a statement.Read More
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions in several European countries, Canada and the U.S. for a pivotal Phase 3 trial of its lead drug candidate, CF101, in the treatment of rheumatoid arthritis (RA).
The Phase 3 protocol submission in Israel follows a successful meeting that Can-Fite concluded on Dec. 8 with the Medical Products Agency (MPA) in Sweden regarding the European registration of CF101 in the treatment of RA.Read More